Stocks of Gilead Sciences, Inc (NASDAQ:GILD) traded higher last session on Wall Street, down -2.58% to $110.09.
GILD stock price is now 3.95% away from the 50-day moving average and 13.95% away from the 200-day moving average. The market capitalization of the company currently stands at $136.94B.
On March 04, 2025, Oppenheimer reiterated its ‘Outperform’ rating on the stock by increasing its target price from $115 to quote $132, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, O’Day Daniel Patrick, Chairman & CEO sold 10,000 shares of the company’s stock on May 30 ’25. The stock was sold for $1,104,193 at an average price of $110.42. Upon completion of the transaction, the Chairman & CEO now directly owns 620,268 shares in the company, valued at $68.29 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 30 ’25, Officer DANIEL O’DAY bought 10,000 shares of the business’s stock. A total of $1,104,192 was incurred on buying the stock at an average price of $110.42. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.69 and a high of $119.96. As of last week, the company has a debt-to-equity ratio of 1.30, a current ratio of 1.37, and a quick ratio of 1.23. The net profit margin was 20.79% and return on equity was 32.51% for GILD.
